Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04603326 · ClinicalTrials.gov registry record
FoxBioNet: ECV (Extracellular Vesicle) 004
A clinical trial of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- Completed
- Registry status
- 140
- Enrollment target
- 4
- Study locations
NCT04603326: Completed study of Parkinson Disease, sponsored by Michael J. Fox Foundation for Parkinson's Research.
NCT04603326 is a study of Parkinson Disease that has completed, run by Michael J. Fox Foundation for Parkinson's Research. The registered enrollment target is 140 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04603326, a study of Parkinson Disease, has completed, sponsored by Michael J. Fox Foundation for Parkinson's Research.
- COMPLETED
- Registry status
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
Primary Outcome
Evaluate each assay performance for ability to detect LRRK2, its activity and/or the detection and activity of the pathways it impacts using a variety of different approaches (quantitative western blot, immunoassays and LC-MS).
Conditions Studied
Interventions
- PROCEDURE Lumbar Puncture
Study Locations (4)
Illinois
- Northwestern University - Chicago
New York
- The Trustees of Columbia University - New York
Oregon
- Oregon Health Sciences Univeristy - Portland
Pennsylvania
- The Trustees of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2023-07-01 |
What the finished NCT04603326 record still lists
NCT04603326 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which Lumbar Puncture is the first listed.
NCT04603326 reports a single indexed study location in Illinois, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT04603326 about?
NCT04603326 is a clinical study titled "FoxBioNet: ECV (Extracellular Vesicle) 004". The goal of this study is to identify reliable markers of LRRK2 activity in human CSF.
What is the current status of trial NCT04603326?
This trial is currently completed. The enrollment target is 140 participants. The study started on 2021-05-06. Estimated completion is 2023-07-01.
What conditions does trial NCT04603326 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT04603326?
The interventions under investigation include: Lumbar Puncture (PROCEDURE).
Who is sponsoring clinical trial NCT04603326?
This trial is sponsored by Michael J. Fox Foundation for Parkinson's Research, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04603326 being conducted?
This trial has 4 study locations across Illinois, New York, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04603326's enrollment target sits among peer trials
140 57th of 297 higher than 239 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease
RECRUITING · NA
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
University of Delaware Parkinson's Disease Registry
RECRUITING
-
Neocortical Microarchitecture of Executive Function
RECRUITING · NA
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI